Qiagen N.V. (QGEN)
After hours:
| Previous Close | 43.57 |
| Open | 43.45 |
| Bid | 42.39 x 900 |
| Ask | 44.23 x 800 |
| Day's Range | 43.19 - 43.48 |
| 52 Week Range | 34.74 - 47.44 |
| Volume | |
| Avg. Volume | 1,275,875 |
| Market Cap | 9.628B |
| Beta (5Y Monthly) | 0.39 |
| PE Ratio (TTM) | 123.77 |
| EPS (TTM) | 0.35 |
| Earnings Date | Jul 31, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jan 30, 2024 |
| 1y Target Est | 50.60 |
GlobeNewswireGlobal TB Summit 2024: QIAGEN leads the charge as tuberculosis reemerges as a leading infectious killer
QIAGEN’s leading tuberculosis blood test QuantiFERON®-TB Gold Plus remains crucial for detection of latent tuberculosis infection, aiding in breaking the cycle of disease transmission // Over 35 top tuberculosis experts to discuss critical topics such as advancements in diagnostics and new treatment strategies // CPD- and CME-accredited event highlights the need for renewed global efforts for tuberculosis controlVenlo, the Netherlands, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Thousands of healthcare pr
ZacksReasons to Retain QIAGEN Stock in Your Portfolio for Now
Investors feel optimistic about QGEN's strong growth prospects in the NGS platforms. Yet, an unfavorable currency impact on the company's operations is cornering.
- Zacks
QIAGEN Launches QIAcuityDx Digital PCR System: Stock to Gain?
QGEN expands its digital PCR portfolio with the newly launched QIAcuityDx Digital PCR System. The system will be used for clinical testing in oncology across North America and Europe.
